BAX Add to watchlist $18.78 0.47 (-2.44%) Last updated: May 31, 2026 04:43
52-Week Range
$18.78
$15.73 $18.78 $32.04

Fundamentals Overview

Baxter International Inc. is near the low of its 52-week range with low valuation, trending downward today.

Valuation low

P/B 1.6 P/S 0.86

Risk (Beta)

0.62 — lower vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 56% confidence Risk: Lower Volatility — Beta 0.62. Diversify and only invest what you can afford to lose.

Pressures (Sell):

Sentiment weakening (3 downgrades) · 3M vs S&P 500: -18.5%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$9.70B
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
1.06%
52-Week Range
$15.73 - $32.04
Volume vs Avg
N/A
Beta
0.62

About

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological...
Sector: Healthcare
Headquarters: US
Employees: 38,000
IPO Date: Oct 1981
Beta: 0.62 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: C+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 1, Equal Weight: 3, Hold: 2, Neutral: 12, Outperform: 3, Overweight: 5, Sell: 1, Underweight: 3.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-2.47; current price is $18.78. That’s a -113.1% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
PEG (TTM) N/A
P/B (TTM) 1.6
P/S (TTM) 0.86
P/FCF (TTM) 13.58
Liquidity & enterprise
Current Ratio (TTM) 1.85
Quick Ratio (TTM) 1.23
Cash Ratio (TTM) 0.55
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -9.7%
Gross margin (TTM) 30.11%
Operating margin (TTM) -2.65%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for BAX.

Analyst Sentiment at a Glance

C+ Sentiment Weakening
Buy 1Equal Weight 3Hold 2Neutral 12Outperform 3Overweight 5Sell 1Underweight 3
0 upgrades, 3 downgrades
Price Target Consensus
Current $18.78
Median $19.50
Consensus $20.00
Low consensus $15.00
High consensus $27.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Citigroup downgrade Neutral Sell 2026-05-28
Barclays maintain Overweight Overweight 2026-05-04
Evercore ISI Group maintain Outperform Outperform 2026-04-06
Citigroup maintain Neutral Neutral 2026-03-11
Goldman Sachs maintain Neutral Neutral 2026-02-17
Barclays maintain Overweight Overweight 2026-02-13
Barclays maintain Overweight Overweight 2026-01-09
Morgan Stanley maintain Underweight Underweight 2025-12-02
Citigroup maintain Neutral Neutral 2025-10-31
UBS maintain Neutral Neutral 2025-10-31
Argus Research downgrade Buy Hold 2025-10-31
Goldman Sachs maintain Neutral Neutral 2025-10-31
Evercore ISI Group maintain Outperform Outperform 2025-10-07
UBS maintain Neutral Neutral 2025-08-04
Barclays maintain Overweight Overweight 2025-08-04
Stifel downgrade Buy Hold 2025-08-04
Wells Fargo maintain Equal Weight Equal Weight 2025-08-01
Morgan Stanley maintain Underweight Underweight 2025-07-15
Citigroup maintain Neutral Neutral 2025-07-09
Evercore ISI Group maintain Outperform Outperform 2025-07-08
Morgan Stanley maintain Underweight Underweight 2025-05-05
Wells Fargo maintain Equal Weight Equal Weight 2025-05-02
Barclays maintain Overweight Overweight 2025-03-10
JP Morgan maintain Neutral Neutral 2025-02-21
Citigroup maintain Neutral Neutral 2024-12-11
Stifel maintain Buy Buy 2024-11-11
Citigroup maintain Neutral Neutral 2024-10-01
Goldman Sachs maintain Neutral Neutral 2024-08-08
Wells Fargo maintain Equal Weight Equal Weight 2024-08-07
JP Morgan maintain Neutral Neutral 2024-08-07